Dose titration study of live attenuated varicella vaccine in healthy children. Pennridge Pediatric Associates.
J Infect Dis
; 175(2): 444-7, 1997 Feb.
Article
in En
| MEDLINE
| ID: mdl-9203669
ABSTRACT
To approximate the effect of prolonged storage on safety and immunogenicity, healthy children were given a single dose of the currently marketed live attenuated varicella vaccine (3625 pfu) or of a partially heat-inactivated vaccine (1125 or 439 pfu). The 3 doses had similar antigen content (attenuated plus inactive virus particles). The vaccine was well tolerated. No significant differences in adverse reactions were observed. Although the seroconversion rates were excellent at each dose (> or = 98%), the higher doses resulted in significantly greater geometric mean antibody titers at 6 weeks (10.5 and 10.6 ELISA U/mL) compared with the 439 pfu dose (5.7 ELISA U/mL), P < or = .01. One year after immunization, differences in antibodies were similar to the 6-week postimmunization results. Results indicate that until the date of expiry, the vaccine's immunogenicity will be preserved and there will be no clinically important changes in type or frequency of adverse events.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vaccines, Inactivated
/
Chickenpox Vaccine
Type of study:
Clinical_trials
/
Risk_factors_studies
Limits:
Child
/
Child, preschool
/
Humans
/
Infant
Language:
En
Journal:
J Infect Dis
Year:
1997
Document type:
Article
Affiliation country: